Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Stock Information for Immuron Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immuron Limited

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain
Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.